Published: 2017-01-04

Comparing the safety and efficacy of intravenous iron sucrose and intravenous ferric carboxymaltose in treating postpartum anemia

Shakun Singh, Vandana Dhama, Rachna Chaudhary, Preeti Singh


Background: Anaemia is the most common hematological abnormality diagnosed during pregnancy. As per WHO, anaemia during pregnancy is defined as haemoglobin concentration of less than 11 gm% (7.45mmol/L) and haematocrit less than 33%. The objective of this study was to compare the safety and efficacy of intravenous iron sucrose and i.v. ferric carboxymaltose in treating postpartum anemia.

Methods: This open label, interventional, prospective study was carried out in 200 postpartum patients with Anemia in the department of obstetrics and gynecology, LLRM Medical College, Meerut, Uttar Pradesh, India from November 2014 to November 2015. The subjects were randomized in 1:1 ratio of two groups. First approved receiving 500 mg of intravenous iron sucrose divided in three doses on alternate days (200 mg, 200 mg, and 100 mg).  Second receiving 500 mg of intravenous ferric carboxymaltose (Ferium, Emcure Pharmaceuticals).

Results: Maximum number of patients of our study belonged to low socioeconomic group, significantly higher number of women achieved Hb >11gm/dl in FCM group.88 women in FCM group achieve Hb rise of 2 gm as compared to only 24 in iron sucrose group, which was highly significant (P value <0.001) mean size of Hb was 2.086 mg for FCM group and 1.766 gm for iron sucrose group, which was also significant. Serum ferritin, which is a marker of iron stores rise much higher 67.6 mg/ml in ferric carboxymaltose group as compared to 47.88 mg/ml for iron sucrose group.

Conclusions: Ferric carboxymaltose is an efficient alternative to Iron Sucrose in treating postpartum anemia. It has an added advantage of single dose regime and lower incidence of side effects.


Iron sucrose, Ferric carboxymaltose, Postpartum anemia

Full Text:



Indian council of medical research evaluation of nutritional anaemia prophylaxis programm task force study New Delhi; 1989.

Center for disease control (CDC), criteria for anaemia in children and child bearing age women MMWR. 1989;38:400-4

Dutta DC. Medical and surgical illness complicating pregnancy. In Konar H, editor. Text book of obstetrics, 7th ed. London, new cenral agency (P) Ltd; 2010:260-261.

Cunninghum FG, Lenevo KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY, Haematological disorder. Editor. Williams obstetrics, 23rd edition. Philadelphia, McGraw Hil; 2010:1080.

Policy on control of nutritional anemia. Ministry of health and Family Walfare, Government of India. Available from; http;// Accessed 1991.

Gupta U. Iron deficiency anemia of pregnancy. In: Trivedi SS, Puri M, Editors. Anemia in pregnancy, 1st edition. New Delhi. jaypee; 2008:45-66.

Breymann C. Treatment of iron deficiency anemia in pregnancy and postpartum. In: Studd J, Tan SL, Chervenak FA, Editors. Current Progress in Obstetrics and Gynaecology, 1st ed. Mumbai: Tree Life Media; 2012:135-148.

Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnefal W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anaemia in inflammatory bowel disease: the ferric carboxy maltose (Ferinject) Randomized Conrlled Trial. Am J Gastroenterol. 2008;103(5):1182-92.

Evstatiev R, Marteau P, Iqbal T, Khaliff IL, Stein J, Bokemeyer B, et al. Fergi study group. Fergicor; a randomized controlled trial on ferric carboxy maltose for iron deficiency anaemia in inflammatory diseases. Gastroenterology. 2011;141(3):846-53.

Grimelt AC, Cohen CD, Fehr T, Serra AL, Wuetrich RP. Safety and tolerability of ferric carboxy maltose (FCM) for treatment of iron deficiency in patient with chronic kidney disease and kidney transplant recipient. Clin Nephrol. 2009;71(2):125-9.

Covic A, Mircescu G, The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing hemodialysis: a multicentre, open label, clinical study. Nephrol Dial Transplant. 2010;25(8):2722-30.

Quinibi WY, Martinez C , Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxy maltose with oral iron for treatment of iron deficiency anaemia of non-dialysis dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599-607.

Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Fair-HF Trial investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.

Wyck DBV, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anaemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;(12):2719-28.

Wyck DBV, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anaemia: randomized controlled trial. Obstet Gynecol. 2007;110:267-78.

Breymann C, Gliga F, BejenariuC, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anaemia. Int J Gynaecol Obstet. 2008;(1):67-73.

Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anaemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435:1-7.

Pfenniger A, Schuller C, Cristoph P, Surbech D. afety and efficacy of high dose intravenous iron carboxymaltose versus iron sucrose for treatment of postpartum anaemia. J Perinat Med. 2012;40(4):397-402.

Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose versus iron sucrose. J Perinat Med. 2012;40(5):469-74.

Verma S, Inamdar SA, Malhoea N. Intravenous vessus oral iron in postpartum patients in rural Ace Jow nal of South Asian federation of oblates and Gynecology May-august; 2011.

Bhendal N Russell R, Intervenes versus oral from therapy for PPA. BJOG. 2006;113:124-5.